Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients

By                            

Oncology Letters, Vol. 10, Iss. 5, 2015-01 ,pp. : 3228-3232

Spandidos Publications

Access to resources Recommend Favorite

Over-Expression of Cancerous Inhibitor of PP2A (CIP2A) in Bone Marrow Cells from Patients with a Group of High-Risk Myelodysplastic Syndromes

By Li Na   Abe Shinya   Kurata Morito   Abe-Suzuki Shiho   Onishi Iichiroh   Kirimura Susumu   Murayama Toshihiko   Hidaka Michihiro   Kawano Fumio   Kitagawa Masanobu  

Pathology & Oncology Research, Vol. 20, Iss. 2, 2014-04 ,pp. : 399-407

Springer Publishing Company

Access to resources Recommend Favorite

Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukaemia

By Martens A.C.M.   Hagenbeek A.  

European Journal of Cancer, Vol. 35, Iss. 4, 1999-04 ,pp. : 634-640

Elsevier

Access to resources Recommend Favorite

Bone marrow hyaluronan and reticulin in patients with malignant disorders

By Sundström G.   Hultdin M.   Engström-Laurent A.   Dahl I.  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 618-623

Humana Press, Inc

Access to resources Recommend Favorite

High-dose Therapy Followed by Autologous Bone Marrow Transplantation in Previously Untreated High Grade Non-Hodgkin's Lymphoma: 10-year Long-term Results

By Zinzani P.L.   Gherlinzoni F.   Bendandi M.   Tura S.  

European Journal of Cancer, Vol. 31, Iss. 13, 1995-12 ,pp. : 2421-2422

Elsevier

Access to resources Recommend Favorite